受强制性开放获取政策约束的文章 - Stephanie de Bono了解详情
无法在其他位置公开访问的文章：1 篇
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial
DJ Wallace, RA Furie, Y Tanaka, KC Kalunian, M Mosca, MA Petri, ...
The Lancet 392 (10143), 222-231, 2018
强制性开放获取政策： US National Institutes of Health, National Institute for Health Research, UK
可在其他位置公开访问的文章：16 篇
Baricitinib plus remdesivir for hospitalized adults with Covid-19
AC Kalil, TF Patterson, AK Mehta, KM Tomashek, CR Wolfe, V Ghazaryan, ...
New England Journal of Medicine 384 (9), 795-807, 2021
强制性开放获取政策： US Department of Defense, US National Institutes of Health, US Department of …
Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 …
VC Marconi, AV Ramanan, S de Bono, CE Kartman, V Krishnan, R Liao, ...
The lancet Respiratory medicine 9 (12), 1407-1418, 2021
强制性开放获取政策： US National Institutes of Health, US Department of Veterans Affairs
Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study
M Dougados, D van der Heijde, YC Chen, M Greenwald, E Drescher, ...
Annals of the rheumatic diseases 76 (1), 88-95, 2017
强制性开放获取政策： National Institute for Health Research, UK
Mechanism of baricitinib supports artificial intelligence‐predicted testing in COVID‐19 patients
J Stebbing, V Krishnan, S de Bono, S Ottaviani, G Casalini, ...
EMBO molecular medicine 12 (8), e12697, 2020
强制性开放获取政策： National Institute for Health Research, UK
Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or …
EW Ely, AV Ramanan, CE Kartman, S de Bono, R Liao, MLB Piruzeli, ...
The Lancet Respiratory Medicine 10 (4), 327-336, 2022
强制性开放获取政策： US National Institutes of Health, US Department of Veterans Affairs
Characterization of the cytokine storm reflects hyperinflammatory endothelial dysfunction in COVID-19
JT Sims, V Krishnan, CY Chang, SM Engle, G Casalini, GH Rodgers, ...
Journal of Allergy and Clinical Immunology 147 (1), 107-111, 2021
强制性开放获取政策： National Institute for Health Research, UK
Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial
CR Wolfe, KM Tomashek, TF Patterson, CA Gomez, VC Marconi, MK Jain, ...
The lancet respiratory medicine 10 (9), 888-899, 2022
强制性开放获取政策： US Department of Defense, US National Institutes of Health, US Department of …
Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies
PC Taylor, JM Kremer, P Emery, SH Zuckerman, G Ruotolo, J Zhong, ...
Annals of the Rheumatic Diseases 77 (7), 988-995, 2018
强制性开放获取政策： National Institute for Health Research, UK
Efficacy and safety of baricitinib in patients with COVID-19 infection: Results from the randomised, double-blind, placebo-controlled, parallel-group COV-BARRIER phase 3 trial
VC Marconi, AV Ramanan, S de Bono, CE Kartman, V Krishnan, R Liao, ...
medRxiv, 2021
强制性开放获取政策： US National Institutes of Health
Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis
P Emery, R Blanco, JM Cocco, YC Chen, CL Gaich, AM DeLozier, ...
RMD open 3 (1), e000410, 2017
强制性开放获取政策： Versus Arthritis, UK, National Institute for Health Research, UK
Characterization and changes of lymphocyte subsets in baricitinib‐treated patients with rheumatoid arthritis: an integrated analysis
Y Tanaka, IB McInnes, PC Taylor, NL Byers, L Chen, S de Bono, M Issa, ...
Arthritis & Rheumatology 70 (12), 1923-1932, 2018
强制性开放获取政策： National Institute for Health Research, UK
Baricitinib plus standard of care for hospitalised adults with covid-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: results of a randomised …
EW Ely, AV Ramanan, CE Kartman, S de Bono, R Liao, MLB Piruzeli, ...
medRxiv, 2021.10. 11.21263897, 2021
强制性开放获取政策： US National Institutes of Health, US Department of Veterans Affairs
Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis
Y Tanaka, B Fautrel, EC Keystone, RA Ortmann, L Xie, B Zhu, M Issa, ...
Annals of the Rheumatic Diseases 78 (7), 890-898, 2019
强制性开放获取政策： National Institute for Health Research, UK
Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial
M Trøseid, JR Arribas, L Assoumou, AR Holten, J Poissy, V Terzić, ...
Critical care 27 (1), 9, 2023
强制性开放获取政策： National Institute of Health and Medical Research, France, Health Research …
Toward accelerated authorization and access to new medicines for juvenile idiopathic arthritis
LE Schanberg, AV Ramanan, F De Benedetti, T Beukelman, GS Eakin, ...
Arthritis & Rheumatology 71 (12), 1976-1984, 2019
强制性开放获取政策： US National Institutes of Health, UK Medical Research Council, Patient …
THU0212 BARICITINIB-ASSOCIATED CHANGES IN GLOBAL GENE EXPRESSION DURING A 24-WEEK PHASE 2 CLINICAL SLE TRIAL DESCRIBE A MECHANISM OF ACTION THROUGH INHIBITION OF JAK/STAT AND …
T Dörner, Y Tanaka, MA Petri, JS Smolen, E Dow, RE Higgs, G Rocha, ...
Annals of the Rheumatic Diseases 78 (Suppl 2), 384-385, 2019
强制性开放获取政策： National Institute of Health and Medical Research, France
出版信息和资助信息由计算机程序自动确定